Statistiche di base
| CIK | 1672619 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Bitwise Funds Trust - Bitwise MARA Option Income Strategy ETF
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| August 13, 2025 |
Calculation of Filing Fee Tables S-3 Enliven Therapeutics, Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39247 ENLIVEN THERAPEUTICS, INC. |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 Enliven Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39247 81-1523849 (State or other jurisdiction of incorporation) (Commiss |
|
| August 13, 2025 |
Exhibit 99.1 Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 47% with 32% of patients achieving MMR by 24 weeks and demonstrating a favorable safety and tolerability profile across all dose levels Strong balance sheet with $491 million in cash, |
|
| August 13, 2025 |
As filed with the Securities and Exchange Commission on August 13, 2025 S-3ASR Table of Contents As filed with the Securities and Exchange Commission on August 13, 2025 Registration No. |
|
| August 13, 2025 |
EX-4.3 Exhibit 4.3 ENLIVEN THERAPEUTICS, INC. INDENTURE Dated as of , 20 [ ] Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 4 Section 1.4 Rules of Construction 5 ARTICLE II THE SECURITIES 5 Section 2.1 Issuable in Series 5 Section 2.2 Est |
|
| June 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2025 Enliven Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39247 81-1523849 (State or other jurisdiction of incorporation) (Commissio |
|
| June 16, 2025 |
8,394,737 Shares of Common Stock Pre-Funded Warrants to Purchase 1,780,263 Shares of Common Stock 424B5 Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration No. 333-272909 PROSPECTUS SUPPLEMENT (To Prospectus dated July 6, 2023) 8,394,737 Shares of Common Stock Pre-Funded Warrants to Purchase 1,780,263 Shares of Common Stock We are offering 8,394,737 shares of our common stock and, in lieu of common stock to investors that so choose, pre-funded warrants to purchase up to 1,780,26 |
|
| June 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2025 Enliven Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39247 81-1523849 (State or other jurisdiction of incorporation) (Commissio |
|
| June 16, 2025 |
Exhibit 1.1 8,394,737 Shares of Common Stock And Pre-Funded Warrants to Purchase 1,780,263 Shares of Common Stock Enliven Therapeutics, Inc. UNDERWRITING AGREEMENT June 13, 2025 JEFFERIES LLC GOLDMAN SACHS & CO. LLC TD SECURITIES (USA) LLC MIZUHO SECURITIES USA LLC As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o GOLDMAN SACHS & CO. L |
|
| June 16, 2025 |
Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Exhibit 99.1 Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants June 13, 2025 BOULDER, COLO., Jun. 13, 2025 (PRNEWSWIRE) – Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has priced its previou |
|
| June 16, 2025 |
Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. Original Issue Date: [ ], 2025 ENLIVEN THERAPEUTICS, INC. Enliven Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered as |
|
| June 13, 2025 |
$200,000,000 Shares of Common Stock Pre-Funded Warrants to Purchase Shares of Common Stock 424B5 Table of Contents As Filed Pursuant to Rule 424(b)5 Registration No. 333-272909 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are part of an effective registration statement relating to these securities filed with the Securities and Exchange Commission under the Securities A |
|
| June 13, 2025 |
EX-99.1 Exhibit 99.1 Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress Reported cumulative MMR rate of 47% (25 of 53) by 24 weeks with 32% (13 of 41) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs ELVN-001 continues to demonstrate a favorable sa |
|
| June 13, 2025 |
As filed with the Securities and Exchange Commission on June 13, 2025 S-3MEF As filed with the Securities and Exchange Commission on June 13, 2025 Registration No. |
|
| June 13, 2025 |
EX-FILING FEES Exhibit 107.1 Calculation of Filing Fee Tables FORM S-3 (Form Type) ENLIVEN THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Pai |
|
| June 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2025 Enliven Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39247 81-1523849 (State or other jurisdiction of incorporation) (Commissio |
|
| May 14, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 Enliven Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39247 81-1523849 (State or other jurisdiction of incorporation) (Commission |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39247 ENLIVEN THERAPEUTICS, INC. |
|
| May 14, 2025 |
Exhibit 99.1 Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update Updated data from the Phase 1 ENABLE clinical trial of ELVN-001 in CML to be presented at the EHA 2025 Congress in June EHA abstract reported cumulative MMR rate of 44% (16 of 36) by 24 weeks with 26% (7 of 27) of patients achieving MMR by 24 weeks, and ELVN-001 remains well-tolerated with 74 p |
|
| April 28, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ De |
|
| April 28, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39247 ENLIVEN THERAP |
|
| March 13, 2025 |
As filed with the Securities and Exchange Commission on March 13, 2025 As filed with the Securities and Exchange Commission on March 13, 2025 Registration No. |
|
| March 13, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2025 Enliven Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39247 81-1523849 (State or other jurisdiction of incorporation) (Commissi |
|
| March 13, 2025 |
Exhibit 107.1 Calculation of Filing Fee Form S-8 (Form Type) Enliven Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value |
|
| March 13, 2025 |
Exhibit 19.1 ENLIVEN THERAPEUTICS, INC. INSIDER TRADING POLICY (As amended on February 6, 2025) A. POLICY OVERVIEW Enliven Therapeutics, Inc. (together with any subsidiaries, collectively “Enliven”) has adopted this Insider Trading Policy (the “Policy”) to help you comply with the federal and state securities laws and regulations that govern trading in securities and to help Enliven minimize its o |
|
| March 13, 2025 |
List of Subsidiaries of Enliven Therapeutics, Inc. Exhibit 21.1 LIST OF SUBSIDIARIES OF ENLIVEN THERAPEUTICS, INC. Name Jurisdiction of Incorporation Enliven Inc. Delaware IMARA Security Corporation Massachusetts |
|
| March 13, 2025 |
Outside Director Compensation Policy, as amended January 1, 2025 Exhibit 10.16 ENLIVEN THERAPEUTICS, INC. OUTSIDE DIRECTOR COMPENSATION POLICY Adopted and approved February 23, 2023 As amended January 1, 2025 (the “Effective Date”) Enliven Therapeutics, Inc. (the “Company”) believes that providing cash and equity compensation to members of its Board of Directors (the “Board,” and members of the Board, the “Directors”) represents an effective tool to attract, re |
|
| March 13, 2025 |
Exhibit 99.1 Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update Updated Phase 1 data for ELVN-001 expected mid-2025 as positive enrollment momentum continues Expected monotherapy and combination data from the ELVN-002 Phase 1 trials in second half of 2025 Strong balance sheet with $313 million in cash, cash equivalents and marketable sec |
|
| November 14, 2024 |
ELVN / Enliven Therapeutics, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm2427451d15sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* ENLIVEN THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 29337E102 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Stat |
|
| November 14, 2024 |
Exhibit 1: Joint Filing Agreement EX-99.1 2 tm2427451d15ex1.htm EXHIBIT 1 EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of November 14, 2024, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commissi |
|
| November 14, 2024 |
ELVN / Enliven Therapeutics, Inc. / CITADEL ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A 1 tm2427061d10sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 2)* Enliven Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (the “Share |
|
| November 14, 2024 |
ELVN / Enliven Therapeutics, Inc. / COMMODORE CAPITAL LP Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Enliven Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 29337E102 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appr |
|
| November 14, 2024 |
SC 13G/A 1 tm2428137d9sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Enliven Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 29337E102 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this State |
|
| November 14, 2024 |
ELVN / Enliven Therapeutics, Inc. / Fairmount Funds Management LLC - SC 13G/A Passive Investment SC 13G/A 1 tm2427721d4sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Enliven Therapeutics, Inc. (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 29337E102 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check |
|
| November 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 Enliven Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39247 81-1523849 (State or other jurisdiction of incorporation) (Commi |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39247 ENLIVEN THERAPEUTICS, INC. |
|
| November 13, 2024 |
Exhibit 99.1 Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 44% (8/18) by 24 weeks and showing that ELVN-001 remains well-tolerated with no dose reductions Continued to progress ELVN-002 with a focus on recently initiated combination clinical t |
|
| November 13, 2024 |
ELVN / Enliven Therapeutics, Inc. / Polar Capital Holdings Plc Passive Investment SC 13G 1 polar-elvn093024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ENLIVEN THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 29337E102 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the a |
|
| August 13, 2024 |
Exhibit 99.1 Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update Dosed the first patient in the Phase 1b arm of the clinical trial evaluating ELVN-001 in patients with CML that is relapsed, refractory or intolerant to available TKIs Dosed the first patient in the Phase 1a clinical trial evaluating ELVN-002 in combination with trastuzumab +/- chemotherapeuti |
|
| August 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 Enliven Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39247 81-1523849 (State or other jurisdiction of incorporation) (Commiss |
|
| August 13, 2024 |
The Company's Restated Certificate of Incorporation, as amended June 18, 2024 Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF IMARA INC. IMARA Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware, does hereby certify that the name of the corporation is IMARA Inc. and the original certificate of incorporation of the corporation was filed with the Secretary of State of the State of Delaware on January 26, 2016. This Restat |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39247 ENLIVEN THERAPEUTICS, INC. |
|
| July 29, 2024 |
ELVN / Enliven Therapeutics, Inc. / 5AM Ventures VI, L.P. - SC 13D/A Activist Investment SC 13D/A 1 tm2420416d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Enliven Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 29337E102 (CUSIP Number) 5AM Venture Management, LLC Attn: Paul A. Stone, Chief Legal Officer 4 |
|
| June 20, 2024 |
As filed with the Securities and Exchange Commission on June 18, 2024 S-8 As filed with the Securities and Exchange Commission on June 18, 2024 Registration No. |
|
| June 20, 2024 |
Exhibit 107.1 Calculation of Filing Fee Form S-8 (Form Type) Enliven Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, pa |
|
| June 18, 2024 |
Amended and Restated 2020 Equity Incentive Plan Exhibit 10.1 ENLIVEN THERAPEUTICS, INC. AMENDED AND RESTATED 2020 EQUITY INCENTIVE PLAN 1. Purpose. The purpose of this Amended and Restated 2020 Equity Incentive Plan (the “Plan”) of Enliven Therapeutics, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expecte |
|
| June 18, 2024 |
Certificate of Amendment to the Company’s Restated Certificate of Incorporation, dated June 18, 2024 Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE RESTATED CERTIFICATE OF INCORPORATION OF ENLIVEN THERAPEUTICS, INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) Enliven Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY: 1. The name of the Corporation is Enliven Therapeutics, Inc |
|
| June 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2024 Enliven Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39247 81-1523849 (State or other jurisdiction of incorporation) (Commissio |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (AMENDMENT NO. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 (April 8, 2024) Enliven Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39247 81-1523849 (State or other jurisd |
|
| May 20, 2024 |
EX-99.1 2 ss3408593ex9901.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that Amendment No. 2 to the Statement on Schedule 13D, dated May 16, 2024, with respect to the common stock of Enliven Therapeutics, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as a |
|
| May 20, 2024 |
ELVN / Enliven Therapeutics, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 2 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) Enliven Therapeutics, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 29337E102 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VII LLC OrbiMed Genesis GP LLC OrbiMed Capital LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 |
|
| May 14, 2024 |
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update Announced positive proof of concept data from Phase 1 clinical trial of ELVN-001 in CML, achieving an initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients Strong balance sheet with $321 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into late 2026 BOULDER, Colo. |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39247 ENLIVEN THERAPEUTICS, INC. |
|
| May 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 Enliven Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39247 81-1523849 (State or other jurisdiction of incorporation) (Commission |
|
| April 30, 2024 |
Enliven Therapeutics, Inc. 6,428,649 Shares of Common Stock Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-278801 PROSPECTUS Enliven Therapeutics, Inc. 6,428,649 Shares of Common Stock This prospectus relates to the offer and resale from time to time of up to 6,428,649 shares (the “Shares”) of our common stock, par value $0.001 per share, by the selling stockholders identified in this prospectus, including their transferees, pledge |
|
| April 26, 2024 |
Enliven Therapeutics, Inc. 6200 Lookout Road Boulder, Colorado 80301 April 26, 2024 Enliven Therapeutics, Inc. 6200 Lookout Road Boulder, Colorado 80301 April 26, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Enliven Therapeutics, Inc. Registration Statement on Form S-3 Filed April 18, 2024 File No. 333-278801 Acceleration Request Requested Date: April 30, 2024 Requested Time: 4:00 p.m. Eastern T |
|
| April 26, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 18, 2024 |
EX-FILING FEES Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-3 (Form Type) Enliven Therapeutics, Inc. |
|
| April 18, 2024 |
As filed with the Securities and Exchange Commission on April 18, 2024 Table of Contents As filed with the Securities and Exchange Commission on April 18, 2024 Registration No. |
|
| April 18, 2024 |
Wilson Sonsini Goodrich & Rosati Professional Corporation 650 Page Mill Road Palo Alto, California 94304-1050 O: 650. |
|
| April 15, 2024 |
ELVN / Enliven Therapeutics, Inc. / 5AM Ventures VI, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Enliven Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 29337E102 (CUSIP Number) 5AM Venture Management, LLC Attn: Paul A. Stone, Chief Legal Officer 4 Embarcadero Center, Suite 3110 San Francis |
|
| April 15, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| April 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2024 Enliven Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39247 81-1523849 (State or other jurisdiction of incorporation) (Commissi |
|
| April 11, 2024 |
Exhibit 99.1 Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia Achieved initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients, which compares favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs Achieved initial cumulative MMR rate of 44% (4/9) by 12 weeks in response-evaluabl |
|
| April 9, 2024 |
Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors Exhibit 99.1 Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) – Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced the appointment of Lori Kunkel, MD, to its Boar |
|
| April 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2024 Enliven Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39247 81-1523849 (State or other jurisdiction of incorporation) (Commissio |
|
| April 4, 2024 |
EX-99.1 2 ss3223565ex9901.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that Amendment No. 1 to the Statement on Schedule 13D, dated April 2, 2024, with respect to the common stock of Enliven Therapeutics, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as |
|
| April 4, 2024 |
ELVN / Enliven Therapeutics, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 1 Activist Investment SC 13D/A 1 ss3223565sc13da.htm AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) Enliven Therapeutics, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 29337E102 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VII LLC OrbiMed Genesis GP LLC OrbiMed Capital LLC 601 |
|
| March 19, 2024 |
Exhibit 99.1 Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates Financing includes participation from new and existing investors Net proceeds, along with existing cash, cash equivalents and marketable securities, are expected to extend cash runway into late 2026 and through multiple key clinical milestones for ELVN-001 and ELVN-002 Company to host |
|
| March 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2024 Enliven Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39247 81-1523849 (State or other jurisdiction of incorporation) (Commissi |
|
| March 19, 2024 |
Exhibit 10.1 [***] Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(a)(6). ENLIVEN THERAPEUTICS, INC. SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (the “Agreement”) is made as of March 19, 2024 (the “Effective Date”), by and among Enliven Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the purchasers whose names and |
|
| March 19, 2024 |
Exhibit 4.1 THESE SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE BUT HAVE BEEN OR WILL BE ISSUED IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND, ACCORDINGLY, MAY NOT BE TRANSFERRED UNLESS (i) S |
|
| March 14, 2024 |
As filed with the Securities and Exchange Commission on March 14, 2024 As filed with the Securities and Exchange Commission on March 14, 2024 Registration No. |
|
| March 14, 2024 |
Exhibit 10.14 AMENDED AND RESTATED CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Amended and Restated Change in Control and Severance Agreement (the “Agreement”) is made between Enliven Therapeutics, Inc. (the “Company”) and Joseph Lyssikatos (the “Executive”). This Agreement provides certain protections to the Executive in connection with a change in control of the Company or in connection with |
|
| March 14, 2024 |
Sam Kintz Change in Control and Severance Agreement, as amended and restated February 29, 2024 Exhibit 10.11 AMENDED AND RESTATED CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Amended and Restated Change in Control and Severance Agreement (the “Agreement”) is made between Enliven Therapeutics, Inc. (the “Company”) and Samuel Kintz (the “Executive”). This Agreement provides certain protections to the Executive in connection with a change in control of the Company or in connection with the i |
|
| March 14, 2024 |
Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update Initial proof of concept data from Phase 1a trial evaluating ELVN-001 in adults with chronic myeloid leukemia (CML) is expected in the second quarter of 2024 IND application to evaluate ELVN-002 in combination with trastuzumab in patients with HER2+ metastatic breast cancer and colorectal cancer received U. |
|
| March 14, 2024 |
Helen Collins Change in Control and Severance Agreement, as amended and restated February 29, 2024 Exhibit 10.12 AMENDED AND RESTATED CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Amended and Restated Change in Control and Severance Agreement (the “Agreement”) is made between Enliven Therapeutics, Inc. (the “Company”) and Helen Collins (the “Executive”). This Agreement provides certain protections to the Executive in connection with a change in control of the Company or in connection with the |
|
| March 14, 2024 |
2020 Employee Stock Purchase Plan Exhibit 10.3 ENLIVEN THERAPEUTICS, INC. 2020 EMPLOYEE STOCK PURCHASE PLAN The purpose of this 2020 Employee Stock Purchase Plan (this “Plan”) is to provide eligible employees of Enliven Therapeutics, Inc. (the “Company”) and certain of its subsidiaries with opportunities to purchase shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”), commencing at such time and o |
|
| March 14, 2024 |
Benjamin Hohl Confirmatory Employment Letter, as amended and restated February 29, 2024 Exhibit 10.8 [***] Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(a)(6) Enliven Therapeutics, Inc. Confirmatory Employment Letter, As Amended and Restated Benjamin Hohl [***] [***] Dear Mr. Hohl: This Confirmatory Employment Letter, as Amended and Restated (the “Agreement”) is entered into between Enliven Therapeutics, Inc. (the “Company” or “we”) and you. T |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39247 ENLIVEN THERAP |
|
| March 14, 2024 |
Joseph Lyssikatos Confirmatory Employment Letter, as amended and restated February 29, 2024 Exhibit 10.9 [***] Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(a)(6) Enliven Therapeutics, Inc. Confirmatory Employment Letter, As Amended and Restated Joseph Lyssikatos [***] [***] Dear Dr. Lyssikatos: This Confirmatory Employment Letter, as Amended and Restated (the “Agreement”) is entered into between Enliven Therapeutics, Inc. (the “Company” or “we”) |
|
| March 14, 2024 |
Description of the Registrant’s Securities Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK The following description of our securities registered under Section 12 of the Exchange Act is intended as a summary only and therefore is not a complete description. This description is based upon, and is qualified by reference to, our restated certificate of incorporation, our amended and restated bylaws and applicable provisions of the Delaware General C |
|
| March 14, 2024 |
Outside Director Compensation Policy, as amended February 13, 2024 Exhibit 10.16 ENLIVEN THERAPEUTICS, INC. OUTSIDE DIRECTOR COMPENSATION POLICY Adopted and approved February 23, 2023 As amended February 13, 2024 (the “Effective Date”) Enliven Therapeutics, Inc. (the “Company”) believes that providing cash and equity compensation to members of its Board of Directors (the “Board,” and members of the Board, the “Directors”) represents an effective tool to attract, |
|
| March 14, 2024 |
Exhibit 97.1 ENLIVEN THERAPEUTICS, INC. COMPENSATION RECOVERY POLICY As adopted on August 15, 2023 Enliven Therapeutics, Inc. (together with any subsidiaries, collectively the “Company”) is committed to strong corporate governance. As part of this commitment, the Company’s Compensation Committee (the “Committee”) of the board of directors (the “Board”) has adopted this clawback policy called the C |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2024 Enliven Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39247 81-1523849 (State or other jurisdiction of incorporation) (Commissi |
|
| March 14, 2024 |
List of Subsidiaries of Enliven Therapeutics, Inc. Exhibit 21.1 LIST OF SUBSIDIARIES OF ENLIVEN THERAPEUTICS, INC. Name Jurisdiction of Incorporation Enliven Inc. Delaware IMARA Security Corporation Massachusetts |
|
| March 14, 2024 |
Benjamin Hohl Change in Control and Severance Agreement, as amended and restated February 29, 2024 Exhibit 10.13 AMENDED AND RESTATED CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Amended and Restated Change in Control and Severance Agreement (the “Agreement”) is made between Enliven Therapeutics, Inc. (the “Company”) and Ben Hohl (the “Executive”). This Agreement provides certain protections to the Executive in connection with a change in control of the Company or in connection with the invol |
|
| March 14, 2024 |
Anish Patel Change in Control and Severance Agreement, as amended and restated February 29, 2024 Exhibit 10.15 AMENDED AND RESTATED CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Amended and Restated Change in Control and Severance Agreement (the “Agreement”) is made between Enliven Therapeutics, Inc. (the “Company”) and Anish Patel (the “Executive”). This Agreement provides certain protections to the Executive in connection with a change in control of the Company or in connection with the in |
|
| March 14, 2024 |
Sam Kintz Confirmatory Employment Letter, as amended and restated February 29, 2024 Exhibit 10.6 [***] Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(a)(6) Enliven Therapeutics, Inc. Confirmatory Employment Letter, As Amended and Restated Samuel Kintz [***] [***] Dear Mr. Kintz: This Confirmatory Employment Letter, as Amended and Restated (the “Agreement”) is entered into between Enliven Therapeutics, Inc. (the “Company” or “we”) and you. T |
|
| March 14, 2024 |
Exhibit 107.1 Calculation of Filing Fee Form S-8 (Form Type) Enliven Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity C |
|
| March 14, 2024 |
Anish Patel Confirmatory Employment Letter, as amended and restated February 29, 2024 Exhibit 10.10 [***] Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(a)(6) Enliven Therapeutics, Inc. Confirmatory Employment Letter, As Amended and Restated Anish Patel [***] [***] Dear Dr. Patel: This Confirmatory Employment Letter, as Amended and Restated (the “Agreement”) is entered into between Enliven Therapeutics, Inc. (the “Company” or “we”) and you. T |
|
| March 14, 2024 |
Helen Collins Confirmatory Employment Letter, as amended and restated February 29, 2024 Exhibit 10.7 [***] Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(a)(6) Enliven Therapeutics, Inc. Confirmatory Employment Letter, As Amended and Restated Helen Collins [***] [***] Dear Dr. Collins: This Confirmatory Employment Letter, as Amended and Restated (the “Agreement”) is entered into between Enliven Therapeutics, Inc. (the “Company” or “we”) and you |
|
| February 16, 2024 |
ELVN / Enliven Therapeutics, Inc. / 5AM Ventures VI, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Enliven Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 29337E102 (CUSIP Number) 5AM Venture Management, LLC Attn: Paul A. Stone, Chief Legal Officer 501 2nd Street, Suite 350 San Francisco, CA |
|
| February 14, 2024 |
SC 13G/A 1 tm246235d7sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Enliven Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 29337E102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Stateme |
|
| February 14, 2024 |
ELVN / Enliven Therapeutics, Inc. / COMMODORE CAPITAL LP Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Enliven Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 29337E102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appro |
|
| February 14, 2024 |
ELVN / Enliven Therapeutics, Inc. / PFIZER INC - SC 13G/A ENLIVEN THERAPEUTICS Passive Investment SC 13G/A 1 enlivenschedule13gaexitfil.htm SC 13G/A ENLIVEN THERAPEUTICS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1 – Exit Filing)1 ENLIVEN THERAPEUTICS, INC. (formerly, IMARA Inc.) (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 29337E102 (CUSIP Number) December 31, 2 |
|
| February 14, 2024 |
ELVN / Enliven Therapeutics, Inc. / CITADEL ADVISORS LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1)* Enliven Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (the “Shares”) (Title of Class of Securities) 29337E10 |
|
| February 14, 2024 |
ELVN / Enliven Therapeutics, Inc. / Fairmount Funds Management LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Enliven Therapeutics, Inc. (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 29337E102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule p |
|
| February 7, 2024 |
ELVN / Enliven Therapeutics, Inc. / BML Investment Partners, L.P. Passive Investment SC 13G/A 1 elvn13g020724.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (AMENDMENT NO. 3 )* Enliven Therapeutics, Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 29337E |
|
| February 2, 2024 |
ELVN / Enliven Therapeutics, Inc. / 5AM Ventures VI, L.P. - SC 13D/A Activist Investment SC 13D/A 1 tm245036d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Enliven Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 29337E102 (CUSIP Number) 5AM Venture Management, LLC Attn: Paul A. Stone, Chief Legal Officer 501 |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 09, 2023 Enliven Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39247 81-1523849 (State or other jurisdiction of incorporation) (Commi |
|
| November 9, 2023 |
Enliven Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update Company on track to deliver initial proof of concept data for ELVN-001 and ELVN-002 in 2024 Strong balance sheet, closing the quarter with $263 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into early 2026 BOULDER, Colo. |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39247 ENLIVEN THERAPEUTICS, INC. |
|
| August 28, 2023 |
ELVN / Enliven Therapeutics Inc / 5AM Ventures VI, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Enliven Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 29337E102 (CUSIP Number) 5AM Venture Management, LLC Attn: Rebecca Lucia, Chief Financial Officer 501 2nd Street, Suite 350 San Francisco, |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 Enliven Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39247 81-1523849 (State or other jurisdiction of incorporation) (Commiss |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39247 ENLIVEN THERAPEUTICS, INC. |
|
| August 10, 2023 |
Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress Continued progress of parallel lead programs, ELVN-001 and ELVN-002, through dose escalation in Phase 1 trials, with initial proof of concept data for both programs expected in 2024 Strong balance sheet, closing the quarter with $278 million in cash, cash equivalents and marketable securities BOULDER, Colo. |
|
| July 6, 2023 |
Up to $200,000,000 Common Stock 424B5 Table of Contents As Filed Pursuant to Rule 424(b)5 Registration No. 333-272909 (To Prospectus dated July 6, 2023) PROSPECTUS SUPPLEMENT Up to $200,000,000 Common Stock We have entered into an Open Market Sale AgreementSM (the “Sales Agreement”) with Jefferies LLC (“Jefferies”) relating to the sale of shares of our common stock, par value $0.001 per share, offered by this prospectus suppleme |
|
| June 29, 2023 |
Enliven Therapeutics, Inc. 6200 Lookout Road Boulder, Colorado 80301 June 29, 2023 Enliven Therapeutics, Inc. 6200 Lookout Road Boulder, Colorado 80301 June 29, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Enliven Therapeutics, Inc. Registration Statement on Form S-3 Filed June 23, 2023 File No. 333-272909 Acceleration Request Requested Date: July 3, 2023 Requested Time: 4:00 p.m. Eastern Time, or |
|
| June 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2023 Enliven Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39247 81-1523849 (State or other jurisdiction of incorporation) (Commissio |
|
| June 26, 2023 |
Exhibit 1.1 [***] Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(a)(6) OPEN MARKET SALE AGREEMENTSM June 23, 2023 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Enliven Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time t |
|
| June 23, 2023 |
FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA INDEX TO FINANCIAL STATEMENTS ENLIVEN THERAPEUTICS, INC. Exhibit 99.1 FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA INDEX TO FINANCIAL STATEMENTS ENLIVEN THERAPEUTICS, INC. Page Report of Independent Registered Public Accounting Firm F-2 Financials Statements as of December 31, 2022 and 2021 and for the years ended December 31, 2022 and 2021 F-3 Balance Sheets F-3 Statements of Operations and Comprehensive Loss F-4 Statements of Convertible Preferred Stoc |
|
| June 23, 2023 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) ENLIVEN THERAPEUTICS, INC. |
|
| June 23, 2023 |
UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION EX-99.2 Exhibit 99.2 UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION Explanatory Note On October 13, 2022, Imara Inc. (“Imara” or the “Company”), Enliven Therapeutics, Inc. (“Enliven”), and a wholly owned subsidiary of Imara, Iguana Merger Sub, Inc. (“Merger Sub”) entered into an agreement and plan of merger (the “Merger Agreement”). Pursuant to the Merger Agreement, among other matters, Merger |
|
| June 23, 2023 |
Form of Specimen Common Stock Certificate (incorporated by reference) Exhibit 4.1 . ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# COMMON STOCK COMMON STOCK PO PAR VALUE $0.001 MR ADD ADD ADD ADD 4321A BOX DESIGNATION SAMPLE Certificate Shares 43004, 0 0 0 0 0 0 (IF Number 0 0 0 0 0 0 ANY) ZQ00000000 0 0 0 0 0 0 PROVIDENCE, ENLIVEN THERAPEUTICS, INC. 0 0 0 0 0 0 RI 0 0 0 0 0 0 INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE Mr. Alexander David Sample Mr. A |
|
| June 23, 2023 |
As filed with the Securities and Exchange Commission on June 23, 2023 S-3 Table of Contents As filed with the Securities and Exchange Commission on June 23, 2023 Registration No. |
|
| June 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2023 Enliven Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39247 81-1523849 (State or other jurisdiction of incorporation) (Commissio |
|
| June 23, 2023 |
Exhibit 1.2 [***] Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(a)(6) OPEN MARKET SALE AGREEMENTSM June 23, 2023 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Enliven Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time t |
|
| June 23, 2023 |
Exhibit 4.3 ENLIVEN THERAPEUTICS, INC. INDENTURE Dated as of , 20 [ ] Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 4 Section 1.4 Rules of Construction 4 ARTICLE II THE SECURITIES 5 Section 2.1 Issuable in Series 5 Section 2.2 Establishment |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39247 ENLIVEN THERAPEUTICS, INC. |
|
| May 11, 2023 |
Anish Patel Change in Control and Severance Agreement, dated February 23, 2023 Exhibit 10.15 ENLIVEN THERAPEUTICS, Inc. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the “Agreement”) is made between Enliven Therapeutics, Inc. (the “Company”) and Anish Patel (the “Executive”), effective as of February 23, 2023 (the “Effective Date”). This Agreement provides certain protections to the Executive in connection with a change in control |
|
| May 11, 2023 |
The Company's Restated Certificate of Incorporation, as amended February 23, 2023 Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF IMARA INC. IMARA Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware, does hereby certify that the name of the corporation is IMARA Inc. and the original certificate of incorporation of the corporation was filed with the Secretary of State of the State of Delaware on January 26, 2016. This Restat |
|
| May 11, 2023 |
Joseph Lyssikatos Confirmatory Employment Letter, dated February 23, 2023 Exhibit 10.9 [***] Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(a)(6) Enliven Therapeutics, Inc. Confirmatory Employment Letter February 23, 2023 Joseph Lyssikatos [***] [***] Dear Dr. Lyssikatos: This letter agreement (the “Agreement”) is entered into between Enliven Therapeutics, Inc. (the “Company” or “we”) and you. This Agreement is effective as of the |
|
| May 11, 2023 |
Anish Patel Confirmatory Employment Letter, dated February 23, 2023 Exhibit 10.10 [***] Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(a)(6) Enliven Therapeutics, Inc. Confirmatory Employment Letter February 23, 2023 Anish Patel [***] [***] Dear Dr. Patel: This letter agreement (the “Agreement”) is entered into between Enliven Therapeutics, Inc. (the “Company” or “we”) and you. This Agreement is effective as of the date sign |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 Enliven Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39247 81-1523849 (State or other jurisdiction of incorporation) (Commission |
|
| May 11, 2023 |
Joseph Lyssikatos Change in Control and Severance Agreement, dated February 23, 2023 Exhibit 10.14 ENLIVEN THERAPEUTICS, Inc. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the “Agreement”) is made between Enliven Therapeutics, Inc. (the “Company”) and Joseph Lyssikatos (the “Executive”), effective as of February 23, 2023 (the “Effective Date”). This Agreement provides certain protections to the Executive in connection with a change in co |
|
| May 11, 2023 |
Exhibit 99.1 Enliven Therapeutics Highlights Business Achievements and Reports First Quarter 2023 Financial Results Successfully completed merger with Imara Inc., trading under the new ticker symbol on Nasdaq, “ELVN” Dosed first patient in Phase 1 study of ELVN-002 in patients with HER2-altered non-small cell lung cancer (NSCLC) and other solid tumors Enrollment progressing in Phase 1 trial with E |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 28, 2023 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 27, 2023 |
ELVN / Enliven Therapeutics Inc / Fairmount Funds Management LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Enliven Therapeutics, Inc. (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 29337E102 (CUSIP Number) April 18, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursua |
|
| April 24, 2023 |
ELVN / Enliven Therapeutics Inc / COMMODORE CAPITAL LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| April 24, 2023 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. |
|
| March 21, 2023 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS EX-99.1 Exhibit 99.1 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS On February 23, 2023, Enliven Therapeutics, Inc. (formerly, Imara Inc.) (the “Company”) completed its business combination with Enliven Inc. (formerly, Enliven Therapeutics, Inc.) (“Enliven”) in accordance with the terms of the Agreement and Plan of Merger, dated as of October 13, 2022 (the “ |
|
| March 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (AMENDMENT No. 1) CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2023 (February 23, 2023) Enliven Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39247 81-1523849 (State or other |
|
| March 21, 2023 |
Exhibit 99.2 FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA INDEX TO FINANCIAL STATEMENTS ENLIVEN THERAPEUTICS, INC. Page Report of Independent Registered Public Accounting Firm F-2 Financials Statements as of December 31, 2022 and 2021 and for the years ended December 31, 2022 and 2021 F-3 Balance Sheets F-3 Statements of Operations and Comprehensive Loss F-4 Statements of Convertible Preferred Stoc |
|
| March 21, 2023 |
UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION EX-99.3 Exhibit 99.3 UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION Explanatory Note On October 13, 2022, Imara Inc. (“Imara” or the “Company”), Enliven Therapeutics, Inc. (“Enliven”), and a wholly owned subsidiary of Imara, Iguana Merger Sub, Inc. (“Merger Sub”) entered into an agreement and plan of merger (the “Merger Agreement”). Pursuant to the Merger Agreement, among other matters, Merger |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Enliven Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 29337E102 (CUSIP Number) March 3, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| March 6, 2023 |
ELVN / Enliven Therapeutics Inc / 5AM Ventures VI, L.P. - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Enliven Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 29337E102 (CUSIP Number) 5AM Venture Management, LLC Attn: Galya Blachman, Ph.D., Esq., General Counsel 501 2nd Street, Suite 350 San Franc |
|
| March 6, 2023 |
ELVN / Enliven Therapeutics Inc / CITADEL ADVISORS LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* Enliven Therapeutics, Inc. (Name of Issuer) Common stock, par value $0.001 per share (the “Shares”) (Title of Class of Securities) 29337E102 |
|
| March 6, 2023 |
EX-99.1 2 tm238639d1ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Shares of Enliven Therapeutics, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 193 |
|
| March 1, 2023 |
EX-99.6 Exhibit 99.6 The references to share and per share amounts in this Exhibit 99.6 to the Company’s Current Report on Form 8-K do not reflect the Reverse Stock Split, as defined in the Company’s Current Report on Form 8-K of which this Exhibit 99.6 is a part. ENLIVEN THERAPEUTICS, INC. INDEX TO FINANCIAL STATEMENTS Unaudited Interim Condensed Financial Statements: Condensed Financial Statemen |
|
| March 1, 2023 |
Form of Indemnification Agreement of the Company EX-10.16 Exhibit 10.16 ENLIVEN THERAPEUTICS, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (this “Agreement”) is dated as of [insert date], and is between Enliven Therapeutics, Inc., a Delaware corporation (the “Company”), and [insert name of indemnitee] (“Indemnitee”). RECITALS A. Indemnitee’s service to the Company substantially benefits the Company. B. Individuals are reluctant |
|
| March 1, 2023 |
Benjamin Hohl Change in Control and Severance Agreement, dated February 23, 2023 EX-10.13 Exhibit 10.13 ENLIVEN THERAPEUTICS, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the “Agreement”) is made between Enliven Therapeutics, Inc. (the “Company”) and Benjamin Hohl (the “Executive”), effective as of February 23, 2023 (the “Effective Date”). This Agreement provides certain protections to the Executive in connection with a change |
|
| March 1, 2023 |
Letter dated March 1, 2023 from Ernst & Young to the Securities and Exchange Commission EX-16.1 Exhibit 16.1 Ernst & Young LLP 200 Clarendon Street Boston, Ma 02116 Tel: (617) 266-2000 Fax: (617) 266-5843 www.ey.com March 1, 2023 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We have read Item 4.01 of Form 8-K dated February 23, 2023, of Enliven Therapeutics, Inc. (Formerly known as IMARA, Inc.) and are in agreement with the statement |
|
| March 1, 2023 |
As filed with the Securities and Exchange Commission on March 1, 2023 S-8 As filed with the Securities and Exchange Commission on March 1, 2023 Registration No. |
|
| March 1, 2023 |
EX-99.3 Exhibit 99.3 ENLIVEN’S BUSINESS References to “we,” “our,” “us”, “our company” and “Enliven” refer to Enliven Therapeutics, Inc. together with its subsidiaries (formerly, Imara Inc.). References to “Former Enliven” refer to Enliven Inc. (formerly, Enliven Therapeutics, Inc.). Capitalized terms not defined herein shall have the meaning granted to them in Enliven’s definitive proxy statement |
|
| March 1, 2023 |
ENLIVEN MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS EX-99.4 Exhibit 99.4 ENLIVEN MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS On February 23, 2023, Enliven Therapeutics, Inc. (formerly Imara Inc.) (the “Company”) completed its business combination with Enliven Inc. (formerly Enliven Therapeutics, Inc.) (“Enliven”) in accordance with the terms of Agreement and Plan of Merger, dated as of October 13, 2022 (the |
|
| March 1, 2023 |
Amendment to the Company’s 2020 Employee Stock Purchase Plan EX-10.5 Exhibit 10.5 AMENDMENT NO. 1 TO ENLIVEN THERAPEUTICS, INC. 2020 EMPLOYEE STOCK PURCHASE PLAN The 2020 Employee Stock Purchase Plan (the “Plan”) of IMARA Inc. is hereby amended as follows: 1. The second sentence of the first paragraph to the Plan shall be deleted in its entirety and replaced with the following: “Subject to adjustment under Section 15 hereof, the number of shares of Common S |
|
| March 1, 2023 |
Helen Collins Confirmatory Employment Letter, dated February 23, 2023 EX-10.9 Exhibit 10.9 [***] Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(a)(6) ENLIVEN THERAPEUTICS, INC. Confirmatory Employment Letter February 23, 2023 Helen Collins [***] [***] Dear Dr. Collins: This letter agreement (the “Agreement”) is entered into between Enliven Therapeutics, Inc. (the “Company” or “we”) and you. This Agreement is effective as of th |
|
| March 1, 2023 |
Sam Kintz Confirmatory Employment Letter, dated February 23, 2023 EX-10.8 Exhibit 10.8 [***] Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(a)(6) ENLIVEN THERAPEUTICS, INC. Confirmatory Employment Letter February 23, 2023 Samuel Kintz [***] [***] Dear Mr. Kintz: This letter agreement (the “Agreement”) is entered into between Enliven Therapeutics, Inc. (the “Company” or “we”) and you. This Agreement is effective as of the d |
|
| March 1, 2023 |
Amended and Restated 2020 Equity Incentive Plan EX-10.2 Exhibit 10.2 ENLIVEN THERAPEUTICS, INC. AMENDED AND RESTATED 2020 EQUITY INCENTIVE PLAN 1. Purpose The purpose of this Amended and Restated 2020 Equity Incentive Plan (the “Plan”) of IMARA Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make |
|
| March 1, 2023 |
Sam Kintz Change in Control and Severance Agreement, dated February 23, 2023 EX-10.11 Exhibit 10.11 ENLIVEN THERAPEUTICS, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the “Agreement”) is made between Enliven Therapeutics, Inc. (the “Company”) and Samuel Kintz (the “Executive”), effective as of February 23, 2023 (the “Effective Date”). This Agreement provides certain protections to the Executive in connection with a change i |
|
| March 1, 2023 |
Code of Business Conduct and Ethics EX-14.1 Exhibit 14.1 ENLIVEN THERAPEUTICS, INC. CODE OF BUSINESS CONDUCT AND ETHICS (Adopted on February 23, 2023) A. PURPOSE This Code of Business Conduct and Ethics (this “Code”) is designed to deter wrongdoing and to promote: 1. fair and accurate financial reporting; 2. compliance with applicable laws, rules and regulations including, without limitation, full, fair, accurate, timely and underst |
|
| March 1, 2023 |
Exhibit 99.1 Enliven Therapeutics Closes Merger with Imara and Private Placement of $165 Million February 23, 2023 Combined company will be focused on advancing Enliven’s clinical-stage pipeline of precision oncology programs Shares to trade on Nasdaq under the new ticker symbol “ELVN” on February 24, 2023 Combined company is expected to have cash runway into early 2026 BOULDER, Colo., Feb. 23, 20 |
|
| March 1, 2023 |
Employee Incentive Compensation Plan EX-10.18 Exhibit 10.18 ENLIVEN THERAPEUTICS, INC. EMPLOYEE INCENTIVE COMPENSATION PLAN 1. Purposes of the Plan. The Plan is intended to increase stockholder value and the success of the Company by motivating Employees to (a) perform to the best of their abilities and (b) achieve the Company’s objectives. 2. Definitions. 2.1 “Actual Award” means as to any Performance Period, the actual award (if an |
|
| March 1, 2023 |
SELECTED HISTORICAL AND UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION EX-99.7 Exhibit 99.7 The references to share and per share amounts in this Exhibit 99.7 to the Company’s Current Report on Form 8-K do not reflect the Reverse Stock Split. Capitalized terms not defined herein shall have the meaning granted to them in the Company’s definitive proxy statement/prospectus filed with the Securities and Exchange Commission on January 23, 2023 (the “definitive proxy stat |
|
| March 1, 2023 |
Outside Director Compensation Policy EX-10.14 Exhibit 10.14 ENLIVEN THERAPEUTICS, INC. OUTSIDE DIRECTOR COMPENSATION POLICY Adopted and approved February 23, 2023 (the “Effective Date”) Enliven Therapeutics, Inc. (the “Company”) believes that providing cash and equity compensation to members of its Board of Directors (the “Board,” and members of the Board, the “Directors”) represents an effective tool to attract, retain and reward Di |
|
| March 1, 2023 |
Benjamin Hohl Confirmatory Employment Letter, dated February 23, 2023 EX-10.10 Exhibit 10.10 [***] Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(a)(6) ENLIVEN THERAPEUTICS, INC. Confirmatory Employment Letter February 23, 2023 Benjamin Hohl [***] [***] Dear Mr. Hohl: This letter agreement (the “Agreement”) is entered into between Enliven Therapeutics, Inc. (the “Company” or “we”) and you. This Agreement is effective as of the |
|
| March 1, 2023 |
EX-3.2 Exhibit 3.2 CERTIFICATE OF AMENDMENT TO THE RESTATED CERTIFICATE OF INCORPORATION OF IMARA INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) Imara Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CERTIFY |
|
| March 1, 2023 |
EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF IMARA INC. Imara Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), does hereby certify as follows: 1. The name of the Corporation is Imara Inc. 2. Article FOURTH of the Res |
|
| March 1, 2023 |
EX-99.2 Exhibit 99.2 RISK FACTORS You should carefully consider the risks described below. The occurrence of any of the following risks could have a material adverse effect on our business, financial condition, results of operations and future growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made or may make from time to t |
|
| March 1, 2023 |
Contingent Value Rights Agreement between the Company and Rights Agent EX-10.1 Exhibit 10.1 [***] Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(a)(6) EXHIBIT C FORM OF CONTINGENT VALUE RIGHTS AGREEMENT BETWEEN IMARA INC. and COMPUTERSHARE INC. AND COMPUTERSHARE TRUST COMPANY, N.A., COLLECTIVELY, AS RIGHTS AGENT Dated as of February 23, 2023 FORM OF CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT (this |
|
| March 1, 2023 |
Rahul Ballal Separation Agreement, dated February 23, 2023 EX-10.6 Exhibit 10.6 SEPARATION AGREEMENT AND GENERAL RELEASE This Separation Agreement and General Release (the “Agreement”) is entered into by and between Imara Inc. (referred to throughout this Agreement as “Employer”) and Rahul Ballal (“Employee”). The term “Party” or “Parties” as used herein shall refer to Employer, Employee, or both, as may be appropriate. The Parties are subject to the term |
|
| March 1, 2023 |
EX-99.5 25 d464771dex995.htm EX-99.5 Exhibit 99.5 The references to share and per share amounts in this Exhibit 99.5 to the Company’s Current Report on Form 8-K do not reflect the Reverse Stock Split, as defined in the Company’s Current Report on Form 8-K of which this Exhibit 99.5 is a part. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA INDEX TO FINANCIAL STATEMENTS ENLIVEN THERAPEUTICS, INC. Page |
|
| March 1, 2023 |
Michael Gray Separation Agreement, dated February 23, 2023 EX-10.7 Exhibit 10.7 SEPARATION AGREEMENT AND GENERAL RELEASE This Separation Agreement and General Release (the “Agreement”) is entered into by and between Imara Inc. (referred to throughout this Agreement as “Employer”) and Michael Gray (“Employee”). The term “Party” or “Parties” as used herein shall refer to Employer, Employee, or both, as may be appropriate. The Parties are subject to the term |
|
| March 1, 2023 |
Helen Collins Change in Control and Severance Agreement, dated February 23, 2023 EX-10.12 Exhibit 10.12 ENLIVEN THERAPEUTICS, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the “Agreement”) is made between Enliven Therapeutics, Inc. (the “Company”) and Helen Collins (the “Executive”), effective as of February 23, 2023 (the “Effective Date”). This Agreement provides certain protections to the Executive in connection with a change |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 Enliven Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39247 81-1523849 (State or other jurisdiction of incorporation) (Commi |
|
| March 1, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Form S-8 (Form Type) Enliven Therapeutics, Inc. |
|
| February 28, 2023 |
ELVN / Enliven Therapeutics Inc / COMMODORE CAPITAL LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 28, 2023 |
LOCK-UP AGREEMENT October 13, 2022 Enliven Therapeutics, Inc. Ladies and Gentlemen: The undersigned signatory of this lock-up agreement (this “Lock-Up Agreement”) understands that Imara Inc., a Delaware corporation (“Public Company”), has entered into an Agreement and Plan of Merger, dated as of October 13, 2022 (as the same may be amended from time to time, the “Merger Agreement”) with Iguana Mer |
|
| February 28, 2023 |
ELVN / Enliven Therapeutics Inc / ORBIMED ADVISORS LLC - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Enliven Therapeutics, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 29337E102 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VII LLC OrbiMed Genesis GP LLC OrbiMed Capital LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) |
|
| February 28, 2023 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated February 23, 2023, with respect to the common stock of Enliven Therapeutics, Inc. |
|
| February 27, 2023 |
IMRA / Imara Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* ENLIVEN THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 45249V107 (CUSIP Number) February 23, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat |
|
| February 22, 2023 |
AMENDMENT NO. 1 IMARA INC. 2020 EMPLOYEE STOCK PURCHASE PLAN EX-99.2 Exhibit 99.2 AMENDMENT NO. 1 TO IMARA INC. 2020 EMPLOYEE STOCK PURCHASE PLAN The 2020 Employee Stock Purchase Plan (the “Plan”) of IMARA Inc. is hereby amended as follows: 1. The second sentence of the first paragraph to the Plan shall be deleted in its entirety and replaced with the following: “Subject to adjustment under Section 15 hereof, the number of shares of Common Stock that have b |
|
| February 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2023 IMARA INC. (Exact name of registrant as specified in its charter) Delaware 001-39247 81-1523849 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| February 22, 2023 |
EX-99.3 Exhibit 99.3 IMARA ANNOUNCES STOCKHOLDER APPROVAL OF MERGER WITH ENLIVEN — Combined Company to Trade on Nasdaq Under Ticker “ELVN” — — Imara Announces 1-for-4 Reverse Stock Split of Common Stock — BROOKLINE, Mass.—Feb. 22, 2023— Imara Inc. (Nasdaq: IMRA) today announced the results of the special meeting of its stockholders held on February 22, 2023. At the special meeting, Imara’s stockho |
|
| February 22, 2023 |
EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF IMARA INC. Imara Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), does hereby certify as follows: 1. The name of the Corporation is Imara Inc. 2. Article FOURTH of the Res |
|
| February 22, 2023 |
IMARA INC. AMENDED AND RESTATED 2020 EQUITY INCENTIVE PLAN EX-99.1 Exhibit 99.1 IMARA INC. AMENDED AND RESTATED 2020 EQUITY INCENTIVE PLAN 1. Purpose The purpose of this Amended and Restated 2020 Equity Incentive Plan (the “Plan”) of IMARA Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contr |
|
| February 22, 2023 |
425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2023 IMARA INC. (Exact name of registrant as specified in its charter) Delaware 001-39247 81-1523849 (State or other jurisdiction of incorporation) (Commission File N |
|
| February 21, 2023 |
IMRA / Imara Inc / COMMODORE CAPITAL LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2023 |
IMRA / Imara Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm236221d30sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* IMARA, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 45249V107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the |
|
| February 14, 2023 |
IMRA / Imara Inc / COMMODORE CAPITAL LP Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Imara Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 45249V107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| February 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2023 IMARA INC. (Exact name of registrant as specified in its charter) Delaware 001-39247 81-1523849 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| February 13, 2023 |
425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2023 IMARA INC. (Exact name of registrant as specified in its charter) Delaware 001-39247 81-1523849 (State or other jurisdiction of incorporation) (Commission File N |
|
| February 10, 2023 |
Exhibit 10.24 January 27, 2023 Enliven Therapeutics, Inc. 6200 Lookout Road Boulder, CO 80301 Attention: General Counsel VIA EMAIL Dear Ms. Blachman: Reference is made to (a) that certain Public Company Support Agreement, dated as of October 13, 2022, by and among Imara Inc., a Delaware corporation (“Imara”), Enliven Therapeutics, Inc., a Delaware corporation ( “Merger Partner”), and Michael Gray, |
|
| February 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39247 IMARA INC. (Exa |
|
| February 8, 2023 |
IMRA / Imara Inc / BML Investment Partners, L.P. - NONE Passive Investment SC 13G/A 1 doc1.htm NONE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* IMARA INC (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 45249V107 (CUSIP Number) Calendar Year 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d |
|
| January 23, 2023 |
PROPOSED MERGER YOUR VOTE IS VERY IMPORTANT Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-268300 PROPOSED MERGER YOUR VOTE IS VERY IMPORTANT To the Stockholders of Imara Inc. and Enliven Therapeutics, Inc., Imara Inc., a Delaware corporation, or Imara, and Enliven Therapeutics, Inc., a Delaware corporation, or Enliven, entered into an Agreement and Plan of Merger, or the Merger Agreement, on October 13, 2022, pursu |
|
| January 19, 2023 |
Imara Inc. 1309 Beacon Street, Suite 300, Office 341 Brookline, MA 02446 January 19, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jenn Do Kevin Vaughn Lauren Hamill Tim Buchmiller Re: Imara Inc. Registration Statement on Form S-4 File No. 333-268300 Request for Acceleration Ladies and Gentlemen: Pursuant to R |
|
| January 9, 2023 |
As filed with the Securities and Exchange Commission on January 6, 2023 S-4/A Table of Contents As filed with the Securities and Exchange Commission on January 6, 2023 Registration No. |
|
| January 9, 2023 |
Form of Preliminary Proxy Card of Imara Inc. EX-99.1 Exhibit 99.1 YOUR VOTE IS IMPORTANT! PLEASE VOTE BY: INTERNET Go To: www.proxypush.com/IMRA Cast your vote online Have your Proxy Card ready Follow the simple instructions to record your vote PHONE Call 1-866-829-5506 Use any touch-tone telephone Have your Proxy Card ready Follow the simple recorded instructions MAIL Mark, sign and date your Proxy Card Fold and return your Proxy Card in th |
|
| January 9, 2023 |
Consulting Agreement between Richard Heyman and Former Enliven [###] Certain exhibits or schedules to this exhibit have been omitted in compliance with Regulation S-K Item 601(a)(5). |
|
| January 6, 2023 |
January 6, 2023 +1 617 526 6000 (t) +1 617 526 5000 (f) wilmerhale.com By Electronic Submission Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Jenn Do Kevin Vaughn Lauren Hamill Tim Buchmiller Re: Imara Inc. Amendment No. 1 to Registration Statement on Form S-4 Filed December 19, 2022 File No. 333-268300 Ladies and Gentlemen: O |
|
| December 19, 2022 |
As filed with the Securities and Exchange Commission on December 19, 2022 Table of Contents As filed with the Securities and Exchange Commission on December 19, 2022 Registration No. |
|
| December 19, 2022 |
December 19, 2022 +1 617 526 6000 (t) +1 617 526 5000 (f) wilmerhale.com By Electronic Submission Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Jenn Do Kevin Vaughn Lauren Hamill Tim Buchmiller Re: Imara Inc. Registration Statement on Form S-4 Filed November 10, 2022 File No. 333-268300 Ladies and Gentlemen: On behalf of Imara |
|
| December 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2022 IMARA INC. (Exact name of registrant as specified in its charter) Delaware 001-39247 81-1523849 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| December 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2022 IMARA INC. (Exact name of registrant as specified in its charter) Delaware 001-39247 81-1523849 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| November 16, 2022 |
UNAUDITED PRO FORMA FINANCIAL INFORMATION EX-99.1 Exhibit 99.1 UNAUDITED PRO FORMA FINANCIAL INFORMATION On November 10, 2022 (the “Closing Date”), IMARA Inc. (the “Company”) completed the previously announced transaction providing for the sale of tovinontrine (IMR-687) and all other assets of the Company related to its PDE9 program (the “Asset Sale”) to Cardurion Pharmaceuticals, Inc. (“Cardurion”) pursuant to the Asset Purchase Agreemen |
|
| November 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 IMARA INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39247 81-1523849 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 10, 2022 |
Consent of Jacob Bauer to be named as a director Exhibit 99.4 Consent to be Named as a Director Nominee In connection with the filing by Imara Inc. (the ?Company?) of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendme |
|
| November 10, 2022 |
Consent of Samuel Kintz to be named as a director Exhibit 99.2 Consent to be Named as a Director Nominee In connection with the filing by Imara Inc. (the ?Company?) of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendme |
|
| November 10, 2022 |
Consent of Richard Heyman, Ph.D., to be named as a director Exhibit 99.7 Consent to be Named as a Director Nominee In connection with the filing by Imara Inc. (the ?Company?) of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendme |
|
| November 10, 2022 |
Consent of Mika Derynck, M.D., to be named as a director EX-99.5 10 d401639dex995.htm EX-99.5 Exhibit 99.5 Consent to be Named as a Director Nominee In connection with the filing by Imara Inc. (the “Company”) of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registrat |
|
| November 10, 2022 |
Consent of Joseph Lyssikatos, Ph.D., to be named as a director Exhibit 99.3 Consent to be Named as a Director Nominee In connection with the filing by Imara Inc. (the ?Company?) of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendme |
|
| November 10, 2022 |
Enliven 2019 Equity Incentive Plan, as amended, including forms of agreements thereunder Exhibit 10.2 ENLIVEN THERAPEUTICS, INC. 2019 EQUITY INCENTIVE PLAN AS AMENDED AUGUST 9, 2022 1. Purposes of the Plan. The purposes of this Plan are: ? to attract and retain the best available personnel for positions of substantial responsibility, ? to provide additional incentive to Employees, Directors and Consultants, and ? to promote the success of the Company?s business. The Plan permits the g |
|
| November 10, 2022 |
Consent of Rishi Gupta to be named as a director Exhibit 99.6 Consent to be Named as a Director Nominee In connection with the filing by Imara Inc. (the ?Company?) of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendme |
|
| November 10, 2022 |
Consent of Andrew Schwab to be named as a director EX-99.9 14 d401639dex999.htm EX-99.9 Exhibit 99.9 Consent to be Named as a Director Nominee In connection with the filing by Imara Inc. (the “Company”) of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registrat |
|
| November 10, 2022 |
EX-FILING FEES 15 d401639dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-4 (Form Type) IMARA INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offeri |
|
| November 10, 2022 |
As filed with the Securities and Exchange Commission on November 10, 2022 Table of Contents As filed with the Securities and Exchange Commission on November 10, 2022 Registration No. |
|
| November 10, 2022 |
Consent of Andrew Phillips, Ph.D., to be named as a director Exhibit 99.8 Consent to be Named as a Director Nominee In connection with the filing by Imara Inc. (the ?Company?) of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendme |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2022 IMARA INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39247 81-1523849 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| November 10, 2022 |
List of Subsidiaries of Imara Inc. Exhibit 21.1 List of Subsidiaries Name Jurisdiction of Incorporation IMARA Security Corporation Massachusetts Iguana Merger Sub, Inc. Delaware |
|
| October 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39247 IMARA INC. |
|
| October 24, 2022 |
IMRA / Imara Inc / COMMODORE CAPITAL LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| October 24, 2022 |
IMRA / Imara Inc / RA CAPITAL MANAGEMENT, L.P. - IMARA, INC. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* IMARA, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 45249V107 (CUSIP Number) October 14, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| October 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of |
|
| October 14, 2022 |
EX-99.1 Exhibit 99.1 Enliven Therapeutics, Inc. and Imara Inc. Announce Definitive Merger Agreement Transcript of Conference Call Held on October 13, 2022 at 5:00 P.M. Eastern Time Operator Good day and welcome to the Enliven Therapeutics/Imara merger announcement conference call. Please note that today’s conference is being recorded for archive purposes. At this time, I’d like to turn the confere |
|
| October 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2022 IMARA INC. (Exact name of registrant as specified in its charter) Delaware 001-39247 81-1523849 (State or other jurisdiction of incorporation) (Commission File Number |
|
| October 14, 2022 |
425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2022 IMARA INC. (Exact name of registrant as specified in its charter) Delaware 001-39247 81-1523849 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| October 13, 2022 |
EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among IMARA INC., IGUANA MERGER SUB, INC. and ENLIVEN THERAPEUTICS, INC. Dated as of October 13, 2022 - i - TABLE OF CONTENTS Page ARTICLE I THE MERGER 2 1.1 Effective Time of the Merger 2 1.2 Closing 2 1.3 Effects of the Merger 2 1.4 Directors and Officers of the Surviving Corporation 2 1.5 Public Company Matters 2 ARTICLE II CONVERSION OF SE |
|
| October 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2022 IMARA INC. (Exact name of registrant as specified in its charter) Delaware 001-39247 81-1523849 (State or other jurisdiction of incorporation) (Commission File Number |
|
| October 13, 2022 |
Form of Contingent Value Rights Agreement EX-10.1 Exhibit 10.1 FORM OF CONTINGENT VALUE RIGHTS AGREEMENT BETWEEN IMARA INC. and [ ] Dated as of [•] FORM OF CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT (this “Agreement”), dated as of [•], is entered into by and among Imara Inc. a Delaware corporation (“Public Company”), and [•], as initial Rights Agent (as defined herein). PREAMBLE WHEREAS, Public Company, Iguan |
|
| October 13, 2022 |
EX-99.2 Merger Announcement October 13, 2022 Exhibit 99.2 Disclaimer About this Presentation For the purposes of this notice, the “presentation” that follows shall mean and include the slides that follow, the oral presentation of the slides by members of management of Imara Inc. (“Imara”) or Enliven Therapeutics, Inc. (“Enliven”) or any person on their behalf, any question and answer session that |
|
| October 13, 2022 |
Form of Imara Support Agreement. EX-10.3 Exhibit 10.3 FORM OF IMARA INC. SUPPORT AGREEMENT This Support Agreement (this “Agreement”) is made and entered into as of [•], 2022, by and among Enliven Therapeutics, Inc. a Delaware corporation (“Merger Partner”), Imara Inc., a Delaware corporation (“Public Company”), and the undersigned stockholder (the “Stockholder”) of Public Company. RECITALS WHEREAS, concurrently with the execution |
|
| October 13, 2022 |
EX-10.4 Exhibit 10.4 FORM OF LOCK-UP AGREEMENT [•], 2022 Imara Inc. Ladies and Gentlemen: The undersigned signatory of this lock-up agreement (this “Lock-Up Agreement”) understands that Imara Inc., a Delaware corporation (“Public Company”), has entered into an Agreement and Plan of Merger, dated as of October 13, 2022 (as the same may be amended from time to time, the “Merger Agreement”) with Igua |
|
| October 13, 2022 |
Form of Enliven Support Agreement EX-10.2 Exhibit 10.2 FORM OF ENLIVEN THERAPEUTICS, INC. SUPPORT AGREEMENT This Support Agreement (this “Agreement”) is made and entered into as of [•], 2022, by and among Enliven Therapeutics, Inc., a Delaware corporation (“Merger Partner”), Imara Inc., a Delaware corporation (“Public Company”), and the undersigned stockholder (the “Stockholder”) of Merger Partner. RECITALS WHEREAS, concurrently w |
|
| October 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2022 IMARA INC. (Exact name of registrant as specified in its charter) Delaware 001-39247 81-1523849 (State or other jurisdiction of incorporation) (Commission File Number |
|
| October 13, 2022 |
Enliven Therapeutics and Imara Announce Merger Agreement EX-99.1 Exhibit 99.1 Enliven Therapeutics and Imara Announce Merger Agreement • Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Enliven’s portfolio of precision oncology programs • Combined company is expected to have a cash balance of approximately $300 million at close, which is expected to provide cash runway through multiple clinical milestones and |
|
| October 7, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi |
|
| September 23, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi |
|
| September 23, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Schedule 14A (Form Type) IMARA INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Transaction Valuation Proposed Maximum Aggregate Value of Transaction (1)(2) Fee rate Amount of Filing Fee Fees to Be Paid $ 34,750,000 (3) 0.0000927 $ 3,221.33 Fees Previously Paid $ 0 0.0000927 $ 0 Total Transaction Valuation $ 34,750,000 Total Fees Due |
|
| September 7, 2022 |
EXHIBIT 10.1 IMARA Inc. [email protected] www.imaratx.com September 6, 2022 Rahul D. Ballal, Ph.D. Dear Rahul, You are a key member of the senior management team of Imara Inc. (the ?Company?). As a result, the Company would like to amend that certain retention agreement (the ?Retention Agreement?), dated May 5, 2022, pursuant to which you are eligible for certain retention benefits should you remai |
|
| September 7, 2022 |
EXHIBIT 2.1 EXECUTION COPY Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. ASSET PURCHASE AGREEMENT This Asset Purchase Agreement (this ?Agreement?) is made and entered into as of September 6, 2022 (the ?Execution Date?) |
|
| September 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2022 IMARA INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39247 81-1523849 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| September 7, 2022 |
EXHIBIT 10.2 IMARA Inc. [email protected] www.imaratx.com September 6, 2022 Michael P. Gray Dear Mike, You are a key member of the senior management team of Imara Inc. (the ?Company?). As a result, the Company would like to amend that certain amended and restated retention agreement (the ?Retention Agreement?), dated May 18, 2022, pursuant to which you are eligible for certain retention benefits sh |
|
| September 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2022 IMARA INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39247 81-1523849 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39247 IMARA INC. |
|
| August 3, 2022 |
Exhibit 10.4 IMARA Inc. 116 Huntington Avenue, 6th Floor Boston, MA 02116 USA [email protected] +1 617 202-2020 www.imaratx.com May 18, 2022 Michael P. Gray Dear Mike, You are a key member of the senior management team of Imara Inc. (the “Company”). As a result, subject to the terms and conditions of this letter agreement, you will be eligible for the following retention benefits should you remain |
|
| July 29, 2022 |
Exhibit 10.1 second aMENDMENT TO, and termination of, office LEASE AGREEMENT THIS SECOND AMENDMENT TO, AND TERMINATION OF, OFFICE LEASE AGREEMENT (this ?Amendment?) is made as of July 21, 2022 (the ?Effective Date?) by and between COLUMBIA REIT ? 116 HUNTINGTON, LLC, a Delaware limited liability company (?Landlord?), and IMARA INC., a Delaware corporation (?Tenant?). RECITALS R.1.Landlord and Tena |
|
| July 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2022 IMARA INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39247 81-1523849 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| June 3, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2022 IMARA INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39247 81-1523849 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I |
|
| May 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* IMARA Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 45249V107 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842-4000 (Name, Address and Tel |
|
| May 6, 2022 |
Exhibit 10.1 SEPARATION AGREEMENT AND GENERAL RELEASE This Separation Agreement and General Release (the ?Agreement?) is entered into by and between Imara Inc. (referred to throughout this Agreement as ?Employer?) and Kenneth M. Attie, M.D. (?Employee?). The term ?Party? or ?Parties? as used herein shall refer to Employer, Employee, or both, as may be appropriate. The Parties are subject to the te |
|
| May 6, 2022 |
Retention Agreement, dated as of May 5, 2022, by and between the Registrant and Michael P. Gray Exhibit 10.4 IMARA Inc. 116 Huntington Avenue, 6th Floor Boston, MA 02116 USA [email protected] +1 617 202-2020 www.imaratx.com May 5, 2022 Michael P. Gray Dear Mike, You are a key member of the senior management team of Imara Inc. (the ?Company?). As a result, subject to the terms and conditions of this letter agreement, you will be eligible for the following retention benefits should you remain e |
|
| May 6, 2022 |
Exhibit 10.2 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions Amendment Number 3 to Exclusive License Agreement This Amendment Number 3 (the ?Amendment?), effective as of April 29, 2022 (the ?Amendment Effective Date?), is |
|
| May 6, 2022 |
Exhibit 10.3 IMARA Inc. 116 Huntington Avenue, 6th Floor Boston, MA 02116 USA [email protected] +1 617 202-2020 www.imaratx.com May 5, 2022 Rahul D. Ballal, Ph.D. Dear Rahul, You are a key member of the senior management team of Imara Inc. (the ?Company?). As a result, subject to the terms and conditions of this letter agreement, you will be eligible for the following retention benefits should you |
|
| May 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39247 IMARA INC. |
